Icatibant Ratiopharm (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in HAE attacks.

The dosage and administration schedule for Icatibant Ratiopharm are determined by the prescribing healthcare professional based on the patient’s clinical condition and regulatory guidelines. Patients should follow the prescriber’s instructions precisely.

Safety data for icatibant acetate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant’s subcutaneous route offers rapid onset of action and does not require plasma‑derived products, making it a distinct option for patients who prefer a synthetic agent.

Icatibant Ratiopharm should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

The medication is given by subcutaneous injection, typically into the abdomen or thigh. A healthcare professional or trained patient can perform the injection using the supplied pre‑filled syringe, following aseptic technique and the prescriber’s dosing instructions.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe hypotension, and rare cases of angioedema unrelated to HAE. Patients should be monitored closely after the first dose and instructed to seek immediate medical attention if they experience signs of a severe allergic reaction.

Icatibant is contraindicated in individuals with a known allergy to icatibant acetate or any component of the formulation. It should also be avoided in patients who have experienced severe hypersensitivity to other bradykinin B2 receptor antagonists.